PMID- 21261674
OWN - NLM
STAT- MEDLINE
DCOM- 20110718
LR  - 20151119
IS  - 1600-0560 (Electronic)
IS  - 0303-6987 (Linking)
VI  - 38
IP  - 5
DP  - 2011 May
TI  - Cutaneous Hodgkin-type lymphoproliferative lesion associated with 
      immunomodulatory therapy for ulcerative colitis.
PG  - 443-7
LID - 10.1111/j.1600-0560.2010.01663.x [doi]
AB  - Immunomodulatory drugs have demonstrated efficacy in the therapy against 
      autoimmune diseases such as rheumatoid arthritis, Crohn's disease or ulcerative 
      colitis. Tumor necrosis factor-alpha (TNF-alpha) represents a target molecule for the 
      treatment of these entities. Use of monoclonal antibodies can block the 
      proinflammatory function of TNF-alpha. It has been shown that this action can 
      reactivate quiescent chronic diseases as well as modify the immune response or 
      potentiate carcinogens, thereby increasing the risk of secondary tumor 
      development. In this context, different types of solid or hematological tumors 
      have been documented. We present the case of a male with chronic ulcerative 
      colitis who secondarily developed a cutaneous Hodgkin-type lymphoproliferative 
      lesion associated with immunodeficiency. This secondary tumor developed after 6 
      months of treatment with anti-TNF-alpha.
CI  - Copyright (c) 2011 John Wiley & Sons A/S.
FAU - Vieites, Begona
AU  - Vieites B
AD  - Pathology Department, Virgen del Rocio Universitary Hospital, Seville, Spain.
FAU - Avila, Rainiero
AU  - Avila R
FAU - Biscuola, Michele
AU  - Biscuola M
FAU - Carvajo, Francisco
AU  - Carvajo F
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20110125
PL  - United States
TA  - J Cutan Pathol
JT  - Journal of cutaneous pathology
JID - 0425124
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Aged
MH  - Anti-Inflammatory Agents/administration & dosage/*adverse effects
MH  - Antibodies, Monoclonal/administration & dosage/*adverse effects
MH  - Colitis, Ulcerative/*drug therapy/*pathology
MH  - Hodgkin Disease/*chemically induced/*pathology
MH  - Humans
MH  - Immunotherapy/adverse effects
MH  - Infliximab
MH  - Male
MH  - Skin Neoplasms/*chemically induced/*pathology
EDAT- 2011/01/26 06:00
MHDA- 2011/07/19 06:00
CRDT- 2011/01/26 06:00
PHST- 2011/01/26 06:00 [entrez]
PHST- 2011/01/26 06:00 [pubmed]
PHST- 2011/07/19 06:00 [medline]
AID - 10.1111/j.1600-0560.2010.01663.x [doi]
PST - ppublish
SO  - J Cutan Pathol. 2011 May;38(5):443-7. doi: 10.1111/j.1600-0560.2010.01663.x. Epub 
      2011 Jan 25.